SANOFI-AVENTIS (EPA:SAN)

BRIEF

published on 03/28/2025 at 21:12, 5 days 5 hours ago

FDA Approves Qfitlia for Hemophilia A and B Treatment

FDA Approval Clinical Trials Hemophilia Treatment Antithrombin-lowering Qfitlia
PRESS RELEASE

published on 03/28/2025 at 21:07, 5 days 5 hours ago

Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia (fitusiran) approved as the first US therapy for hemophilia A or B with or without inhibitors, offering consistent protection with few injections, using unique mechanism to reduce bleeding episodes

Fitusiran Hemophilia Qfitlia Antithrombin-lowering Therapy Bleed Protection
BRIEF

published on 03/28/2025 at 07:05, 5 days 19 hours ago

Dupixent Approved in Japan as First Biologic for COPD

Japan Dupixent COPD Treatment Sanofi-Aventis Biologic Approval
PRESS RELEASE

published on 03/28/2025 at 07:00, 5 days 19 hours ago

Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD

Japan COPD Dupixent Phase 3 Results Biologic Medicine
PRESS RELEASE

published on 03/24/2025 at 19:27, 9 days 7 hours ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/24/2025 at 07:35, 9 days 19 hours ago

Sanofi launches the “Q1 2025 Aide mémoire” document

Financial Results Investors Sanofi Q1 2025 Memory Aid
PRESS RELEASE

published on 03/24/2025 at 07:30, 9 days 19 hours ago

Press Release: Availability of the Q1 2025 Aide mémoire
Sanofi announced the availability of the Q1 2025 Aide mémoire on its website to assist in financial modeling, including non-comparable items and first quarter reminders

Sanofi Financial Modeling Aide Mémoire Q1 2025 Exclusivity Losses
PRESS RELEASE

published on 03/10/2025 at 21:09, 23 days 5 hours ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 03/08/2025 at 19:05, 25 days 7 hours ago

Sanofi-Aventis Reports Positive Data for Dupixent in Bullous Pemphigoid

Clinical Study Dupixent Type 2 Inflammation Bullous Pemphigoid Regulatory Review
PRESS RELEASE

published on 03/08/2025 at 19:00, 25 days 7 hours ago

Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive pivotal data for Dupixent in bullous pemphigoid presented at AAD, showing significant disease remission and reduction in severity, itch, and medication use. Regulatory submissions under review in US and EU

Dupixent Type 2 Inflammation Bullous Pemphigoid AAD Sustained Remission

Published on 04/03/2025 at 01:35, 1 hour 4 minutes ago

GMV Minerals Inc. Closes Non-Brokered Financing/ Engages Investor Relations Firm
Published on 04/02/2025 at 23:35, 3 hours 4 minutes ago

Murchison Minerals to Seek Shareholders’ Approval for Share Consolidation
Published on 04/02/2025 at 20:00, 6 hours 39 minutes ago

Network-1 Announces Acquisition of Patent Portfolio
Published on 04/02/2025 at 17:25, 9 hours 14 minutes ago

SOBRsafe Announces Reverse Stock Split
Published on 04/02/2025 at 15:00, 11 hours 39 minutes ago

Doubleview Gold Corp 2025 Exploration Program

View all ACCESSWIRE

Published on 04/02/2025 at 20:20, 6 hours 18 minutes ago

EQS-Adhoc: Siemens Aktiengesellschaft: Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences
Published on 04/02/2025 at 20:01, 6 hours 37 minutes ago

Annual General Meeting of Deutsche Konsum REIT-AG successfully held
Published on 04/02/2025 at 20:01, 6 hours 38 minutes ago

Travis Perkins: Publication of the Annual Report and Accounts 2024
Published on 04/02/2025 at 19:40, 6 hours 58 minutes ago

LION E-Mobility AG starts successfully into the new 2025 financial year – Challenging market environment impacts 2024
Published on 04/02/2025 at 19:13, 7 hours 26 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS

Published on 04/03/2025 at 00:37, 2 hours 1 minute ago

Publication of the report on payments made to governments provided by article L.225-102-3 of the French Commercial Code
Published on 04/02/2025 at 18:05, 8 hours 34 minutes ago

Financial statements - 31 december 2024
Published on 04/02/2025 at 17:45, 8 hours 54 minutes ago

Aéroports de Paris SA - Voting rights as of 31 March 2025
Published on 04/02/2025 at 17:45, 8 hours 54 minutes ago

Availability of the Pre-Q1 2025 Sales Communication
Published on 04/02/2025 at 17:45, 8 hours 54 minutes ago

Information concerning the total number of voting rights and shares 2025 03 31

View all LES ECHOS COMFI WIRE

News